Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity. ##STR00001##

The present invention relates to a compound of general formula (1) and a preparation method therefor, and use of the compound of formula (1) and isomers, crystalline forms and pharmaceutically acceptable salts thereof as an irreversible inhibitor for a K-Ras G12C mutant protein in preparing a medicament for resisting Ras-related diseases such as tumors. ##STR00001##

The present invention relates to novel heterocyclic compounds useful in preparing drugs for the prevention or treatment of diseases associated with STAT3 protein. Specifically, these drugs are useful in the prevention or treatment of solid tumors, blood cancers, radiation or drug-resistant cancers, metastatic cancers, inflammatory diseases, immune system diseases, diabetes, macular degeneration, papillomavirus infections and tuberculosis.

The present invention relates to novel heterocyclic compounds useful in preparing drugs for the prevention or treatment of diseases associated with STAT3 protein. Specifically, these drugs are useful in the prevention or treatment of solid tumors, blood cancers, radiation or drug-resistant cancers, metastatic cancers, inflammatory diseases, immune system diseases, diabetes, macular degeneration, papillomavirus infections and tuberculosis.

Disclosed are compounds including a structural unit of formula (I). Also provided are organic functional films containing the compounds. Further provided are optoelectronic devices containing the compounds and the organic functional films. The compound according to the present disclosure has a large molar extinction coefficient and fluorescence emission efficiency, and a color conversion layer made of the compound can effectively absorb incident light, facilitating preparation of a thin color conversion layer; moreover, the absorption spectrum of the compound can be adjusted by modifying the molecular structure of the compound, different types of color conversion layers can be prepared by using compounds having different chemical structures to absorb light of different colors, and display devices having high color gamut can be manufactured by using the color conversion layers in combination with light-emitting materials having narrow full widths at half maximum and different colors.

##STR00001##

The present invention relates to a compound of formula (I) ##STR00001##
or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y.sup.1 is a 9- or 10-membered bicyclic heteroaryl, Y.sup.2 is a 5-membered heteroaryl, Z.sup.1 is selected from (CO)R.sup.9, S(O)R.sup.9 and S(O.sub.2)R.sup.9, L is an alkyl-, cycloalkyl- or heterocycloalkyl-based linker, and R.sup.1 and R.sup.9 may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.

The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

Methods and systems and compounds and agents for the induction or modulation of ferroptosis in a cell, a tissue, or a tumor in a subject are provided. Various agents and compounds are described. Various methods of administration are described for optimal ferroptosis modulation, for instance, induction and killing of target cells. Methods of making, purifying, and characterizing various compounds are described.

Methods and systems and compounds and agents for the induction or modulation of ferroptosis in a cell, a tissue, or a tumor in a subject are provided. Various agents and compounds are described. Various methods of administration are described for optimal ferroptosis modulation, for instance, induction and killing of target cells. Methods of making, purifying, and characterizing various compounds are described.